XOLFRIA Trademark

Trademark Overview

On Thursday, November 17, 2016, a trademark application was filed for XOLFRIA with the United States Patent and Trademark Office. The USPTO has given the XOLFRIA trademark a serial number of 87240320. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 13, 2020. This trademark is owned by Eli Lilly and Company. The XOLFRIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, dementia, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, sleep disorders; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases
xolfria

General Information

Serial Number87240320
Word MarkXOLFRIA
Filing DateThursday, November 17, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 13, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, dementia, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, sleep disorders; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 23, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events

Event DateEvent Description
Monday, July 13, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 13, 2020ABANDONMENT - NO USE STATEMENT FILED
Thursday, November 28, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 27, 2019EXTENSION 5 GRANTED
Friday, November 22, 2019EXTENSION 5 FILED
Friday, November 22, 2019TEAS EXTENSION RECEIVED
Tuesday, November 19, 2019CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Monday, November 18, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Saturday, May 11, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 9, 2019EXTENSION 4 GRANTED
Thursday, May 9, 2019EXTENSION 4 FILED
Thursday, May 9, 2019TEAS EXTENSION RECEIVED
Tuesday, November 27, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 26, 2018EXTENSION 3 GRANTED
Friday, November 16, 2018EXTENSION 3 FILED
Friday, November 16, 2018TEAS EXTENSION RECEIVED
Tuesday, June 5, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 4, 2018EXTENSION 2 GRANTED
Thursday, May 31, 2018EXTENSION 2 FILED
Thursday, May 31, 2018TEAS EXTENSION RECEIVED
Thursday, November 30, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 29, 2017EXTENSION 1 GRANTED
Tuesday, November 21, 2017EXTENSION 1 FILED
Monday, November 27, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, November 21, 2017TEAS EXTENSION RECEIVED
Tuesday, June 6, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 11, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 11, 2017PUBLISHED FOR OPPOSITION
Wednesday, March 22, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 28, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, February 23, 2017ASSIGNED TO EXAMINER
Monday, February 6, 2017TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Monday, February 6, 2017TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, November 23, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, November 21, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

xolfria diseases disorders preparations diagnostic neurodegenerative pharmaceutical migraines parkinson pain disease